Staff physician: Pulmonary and Critical Care Medicine in Medical and Cardiovascular Intensive Care Units, Regions Hospital; Staff Pulmonologist at The Lung and Sleep Clinic, HealthPartners Specialty Center, St. Paul; Director of the Medical Intensive Care Unit, HealthPartners Medical Group, St. Paul; and Section Head and Department Chair of Critical Care Medicine, Regions Hospital.
Education and training: MD, University of Minnesota Medical School, Minneapolis; Internship in Pediatric and Internal Medicine. Residency in Internal Medicine , University of Minnesota Medical School, Minneapolis; Clinical Chief Resident, Veterans Affairs Medical Center, Minneapolis, MN; Fellow in Pulmonary and Critical Care Medicine, University of Minnesota Medical School, Minneapolis.
Overview of research interests: Dr. Ham began her career in research as an undergrad with a National Science Foundation grant in basic thermodynamics for cryotherapy of cancer cells. In medicine, she had the opportunity to work within a National Institutes of Health training grant-sponsored setting. She developed two clinical prediction models (logistic regression and neural networking) to estimate the duration of mechanical ventilation in patients with acute respiratory distress syndrome. As the Department Chair for Critical Care Medicine and the Medical Director of the Medical Intensive Care Unit (MICU), Dr. Ham has designed and participated in clinical studies associated with septic shock, severe pneumonia, cardiac arrest, and pragmatic trials focused on optimizing the culture of caring for critically ill patients by eliminating unnecessary variability in treatments by incorporating standards of care.
Current research activities and funding:
- Site PI, Early Access Program: “The Use of Angiotensin-II in Patients with Severe Septic Shock Requiring Intensive Pressor Support”
- Site PI, “A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Moxifloxacin IV/PO for Treating Adult Subjects with Community-Acquired Bacterial Pneumonia (CABP).” Funder: Paratek Pharma, LLC.
- Site PI, “Expanded Access for LJPC-501.” Funder: La Jolla Pharmaceuticals.